Drug Profile
Ifidancitinib - Aclaris Therapeutics/Rigel Pharmaceuticals
Alternative Names: A 301; ATI 50002; ATI-502Latest Information Update: 09 Dec 2022
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals
- Developer Aclaris Therapeutics
- Class Amines; Aniline compounds; Anti-inflammatories; Benzoxazoles; Fluorobenzenes; Pyrimidines; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alopecia areata
Highest Development Phases
- Discontinued Alopecia; Alopecia areata; Atopic dermatitis; Vitiligo
Most Recent Events
- 09 Dec 2022 Discontinued - Phase-II for Alopecia areata (Treatment-experienced) in USA (Topical) (Rigel Pharmaceuticals and Aclaris Therapeutics pipeline, December 2022)
- 09 Dec 2022 Discontinued - Phase-II for Alopecia areata in Australia (Topical) (Rigel Pharmaceuticals and Aclaris Therapeutics pipeline, December 2022)
- 09 Dec 2022 Discontinued - Phase-II for Alopecia in USA (Topical) (Rigel Pharmaceuticals and Aclaris Therapeutics pipeline, December 2022)